Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive about its productive presentation at the annual Transcatheter Cardiovascular Therapeutics (TCT) medical conference, the world’s largest interventional cardiology conference. 30-Day clinical data was presented for its full cohort of 13 patients implanted with DurAVR™ THV during its First-In-Human trial. It compared the results with outcomes of its most recent 22 patient study, which showed DurAVR™ THV technology performed favourably against other transcatheter aortic valve replacements and surgical aortic valve replacements at six months.
Anteris Technologies has valve world talking about 'human-like characteristics' of DurAVR
